Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing

Journal of Laboratory Automation

Volumn 21, Issue 1, 2016, Pages 27-36

  Kulesskiy, Evgeny ^a   Saarela, Jani ^a   Turunen, Laura ^a   Wennerberg, Krister ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

acoustic droplet ejection; automated biology; compound management; informatics and software; statistics

Indexed keywords

ASSAYS; CELLS; CYTOLOGY; DISEASES; DROPS; ONCOLOGY; SIGNAL TRANSDUCTION; STATISTICS;

ACOUSTIC DROPLET EJECTIONS; COMPOUND MANAGEMENT; DRUG COMBINATIONS; INFORMATICS; MOLECULAR MEDICINE; MOLECULAR PROFILING; RESISTANCE TESTING; UNIVERSITY OF HELSINKI;

SOFTWARE TESTING;

ACOUSTIC DROPLET EJECTION; ACOUSTICS; ARTICLE; CANCER GENETICS; CANCER MEDICINE; CANCER THERAPY; CLINICAL MEDICINE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; ELECTRONICS; HUMAN; HUMAN CELL; LABORATORY AUTOMATION; MOLECULAR BIOLOGY; MOLECULAR MEDICINE; QUALITY CONTROL PROCEDURES; QUANTITATIVE ASSAY; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; DRUG SCREENING; FINLAND; NEOPLASMS; PERSONALIZED MEDICINE; PROCEDURES; UNIVERSITY HOSPITAL;

ANTINEOPLASTIC AGENT;

ACOUSTICS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; CYTOLOGICAL TECHNIQUES; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FINLAND; HOSPITALS, UNIVERSITY; HUMANS; NEOPLASMS; PRECISION MEDICINE;

EID: 84955467524     PISSN: 22110682     EISSN: 22110690     Source Type: Journal    
DOI: 10.1177/2211068215618869     Document Type: Article

References (20)

1. R.H.ShoemakerThe NCI60 Human Tumour Cell Line Anticancer Drug Screen. Nat. Rev. Cancer2006, 6, 813–823.
2. U.McDermottS.V.SharmaL.Dowell. Identification of Genotype-Correlated Sensitivity to Selective Kinase Inhibitors by Using High-Throughput Tumor Cell Line Profiling. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 19936–19941.
3. H.J.BursteinP.B.ManguM.R.Somerfield. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays. J. Clin. Oncol. 2011, 29, 3328–3330.
4. L.BracciG.SchiavoniA.Sistigu. Immune-Based Mechanisms of Cytotoxic Chemotherapy: Implications for the Design of Novel and Rationale-Based Combined Treatments against Cancer. Cell Death Differ. 2014, 21, 15–25.
5. T.PemovskaM.KontroB.Yadav. Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. Cancer Discov. 2013, 3, 1416–1429.
6. J.BarretinaG.CaponigroN.Stransky. The Cancer Cell Line Encyclopedia Enables Predictive Modelling of Anticancer Drug Sensitivity. Nature2012, 483, 603–607.
7. M.J.GarnettE.J.EdelmanS.J.Heidorn. Systematic Identification of Genomic Markers of Drug Sensitivity in Cancer Cells. Nature2012, 483, 570–575.
8. A.BasuN.E.BodycombeJ.H.Cheah. An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules. Cell2013, 154, 1151–1161.
9. B.Haibe-KainsN.El-HachemN.J.Birkbak. Inconsistency in Large Pharmacogenomic Studies. Nature2013, 504, 389–393.
10. C.HatzisP.L.BedardN.J.Birkbak. Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?Cancer Res. 2014, 74, 4016–4023.
11. B.YadavT.PemovskaA.Szwajda. Quantitative Scoring of Differential Drug Sensitivity for Individually Optimized Anticancer Therapies. Sci. Rep. 2014, 4, 5193.
12. T.PemovskaE.JohnsonM.Kontro. Axitinib Effectively Inhibits BCR-ABL1(T315I) with a Distinct Binding Conformation. Nature2015, 519, 102–105.
13. J.H.ZhangT.D.ChungK.R.OldenburgA Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999, 4, 67–73.
14. J.P.MpindiS.PotdarD.Bychkov. Impact of Normalization Methods on High-Throughput Screening Data with High Hit Rates and Drug Testing with Dose-Response Data. Bioinformatics, in press.
15. X.D.ZhangA Pair of New Statistical Parameters for Quality Control in RNA Interference High-Throughput Screening Assays. Genomics2007, 89, 552–561.
16. L.ChiaraviglioJ.E.KirbyEvaluation of Impermeant, DNA-Binding Dye Fluorescence as a Real-Time Readout of Eukaryotic Cell Toxicity in a High Throughput Screening Format. Assay Drug Dev. Technol. 2014, 12, 219–228.
17. R.SpeerJ.D.WulfkuhleL.A.Liotta. Reverse-Phase Protein Microarrays for Tissue-Based Analysis. Curr. Opin. Mol. Ther. 2005, 7, 240–245.
18. S.K.LeivonenR.MakelaP.Ostling. Protein Lysate Microarray Analysis to Identify MicroRNAs Regulating Estrogen Receptor Signaling in Breast Cancer Cell Lines. Oncogene2009, 28, 3926–3936.
19. S.LuoN.B.WehrR.L.LevineQuantitation of Protein on Gels and Blots by Infrared Fluorescence of Coomassie Blue and Fast Green. Anal. Biochem. 2006, 350, 233–238.
20. S.J.DuellmanW.ZhouP.Meisenheimer. Bioluminescent, Nonlytic, Real-Time Cell Viability Assay and Use in Inhibitor Screening. Assay Drug Dev. Technol. 2015, 13, 456–465.